Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Granisetron

R J Ignoffo

    Cancer Practice
    |May 1, 1994
    PubMed
    Summary
    This summary is machine-generated.

    Granisetron, a 5-HT3 receptor antagonist, effectively prevents chemotherapy-induced emesis, matching ondansetron's efficacy and safety. Further research will clarify its role in managing nausea and vomiting from cancer treatments.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Temozolomide. A new option for high-grade astrocytomas.

    Cancer practice·2002
    Same author

    Arsenic trioxide for the treatment of acute promyelocytic leukemia.

    Cancer practice·2002
    Same author

    Novel oral fluoropyrimidines in the treatment of metastatic colorectal cancer.

    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·1999
    Same author

    Capecitabine: A new oral fluoropyrimidine.

    Cancer practice·1998
    Same author

    Angiogenesis inhibitors. A promising role in cancer therapy.

    Cancer practice·1998
    Same author

    Dolasetron. A new 5-hydroxytryptamine3 receptor antagonist.

    Cancer practice·1997
    Same journal

    Darbepoetin alfa: a review of its use in patients with cancer.

    Cancer practice·2002
    Same journal

    Cancer genetics: information sources for patients and families.

    Cancer practice·2002
    Same journal

    Bladder cancer: epidemiology, diagnosis, and management.

    Cancer practice·2002
    Same journal

    Patient and caregiver interest in internet-based cancer services.

    Cancer practice·2002
    Same journal

    Tapestry: a retreat program of support for persons living with cancer.

    Cancer practice·2002
    Same journal

    Viatical settlements: effects on terminally ill patients.

    Cancer practice·2002
    See all related articles

    Area of Science:

    • Pharmacology
    • Oncology
    • Gastroenterology

    Background:

    • Chemotherapy often causes acute emesis, significantly impacting patient quality of life.
    • 5-HT3 receptor antagonists are a key therapeutic class for managing chemotherapy-induced nausea and vomiting (CINV).
    • Granisetron represents a new option within this established drug class.

    Purpose of the Study:

    • To evaluate the efficacy and safety of granisetron for preventing acute emesis in cancer chemotherapy patients.
    • To compare granisetron's effectiveness against existing treatments, such as ondansetron.
    • To establish granisetron's potential role in supportive cancer care.

    Main Methods:

    • Clinical trials assessing granisetron's antiemetic properties.
    • Comparative analysis of granisetron versus ondansetron in preventing acute chemotherapy-induced emesis.

    Related Experiment Videos

  • Evaluation of toxicity and adverse event profiles for granisetron.

    • Main Results:

    • Granisetron demonstrates equal efficacy to ondansetron as a first-line agent for acute chemotherapy-induced emesis prophylaxis.
    • The drug exhibits a similar low toxicity profile compared to ondansetron.
    • Granisetron is positioned for market release, offering a new therapeutic choice.

    Conclusions:

    • Granisetron is a highly effective and safe option for preventing acute chemotherapy-induced emesis.
    • It provides comparable benefits to ondansetron, expanding treatment choices for CINV.
    • Ongoing studies are necessary to fully define granisetron's optimal application in clinical practice.